Citi analyst Mohit Bansal upgraded Radius Health to Buy from Neutral and raised his price target for the shares to $40 from $24. The analyst's close look at the patch clinical trial indicates a "reasonable likelihood of success." Patch can at least double the market and could help Tymlos generate combined sales of $830M by 2028, Bansal tells investors in a research note. With patch and Elacestrant data expected in 2021, investors might start to get in the name later this year or early next year, says the analyst. He sees fair value for Radius Health shares of $54 to $100 if the patch works.